Biolojic AI-designed antibody license (BD9)
Research partnerships Announcement
Disclosed: Verified: Partners: Biolojic Design
Teva and Biolojic announced an exclusive license to develop a potential antibody therapy for atopic dermatitis and asthma. The release describes Biolojic as a company that uses computational biology and artificial intelligence to design antibodies.
Source
Company Archive pending